PYC Therapeutics Ltd
ASX:PYC
PYC Therapeutics Ltd
Total Current Liabilities
PYC Therapeutics Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Current Liabilities
AU$11m
|
CAGR 3-Years
11%
|
CAGR 5-Years
57%
|
CAGR 10-Years
29%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Current Liabilities
$102.6m
|
CAGR 3-Years
26%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Total Current Liabilities
$4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Current Liabilities
AU$1.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Current Liabilities
AU$17.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
22%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Current Liabilities
AU$231.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
Glance View
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
See Also
What is PYC Therapeutics Ltd's Total Current Liabilities?
Total Current Liabilities
11m
AUD
Based on the financial report for Dec 31, 2025, PYC Therapeutics Ltd's Total Current Liabilities amounts to 11m AUD.
What is PYC Therapeutics Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
29%
Over the last year, the Total Current Liabilities growth was -3%. The average annual Total Current Liabilities growth rates for PYC Therapeutics Ltd have been 11% over the past three years , 57% over the past five years , and 29% over the past ten years .
